Polymicrogyria with optic nerve hypoplasia

disease
On this page

Also known as CDCBM8

Summary

Polymicrogyria with optic nerve hypoplasia (MONDO:0013172) is a disease with 1 cohort gene.

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Cohort genes: 1
  • ClinVar variants: 8
  • Phenotypes (HPO): 14

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families4WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

14 HPO clinical features (Orphanet curated; top 14 by frequency):

HPO IDTermFrequency
HP:0000609Optic nerve hypoplasiaVery frequent (80-99%)
HP:0000707Abnormality of the nervous systemVery frequent (80-99%)
HP:0001250SeizureVery frequent (80-99%)
HP:0001265HyporeflexiaVery frequent (80-99%)
HP:0001319Neonatal hypotoniaVery frequent (80-99%)
HP:0001344Absent speechVery frequent (80-99%)
HP:0002126PolymicrogyriaVery frequent (80-99%)
HP:0011344Severe global developmental delayVery frequent (80-99%)
HP:0030048ColpocephalyVery frequent (80-99%)
HP:0001274Agenesis of corpus callosumFrequent (30-79%)
HP:0002069Bilateral tonic-clonic seizureFrequent (30-79%)
HP:0002365Hypoplasia of the brainstemOccasional (5-29%)
HP:0006989Dysplastic corpus callosumOccasional (5-29%)
HP:0012469Infantile spasmsOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namepolymicrogyria with optic nerve hypoplasia
Mondo IDMONDO:0013172
MeSHC567715
OMIM613180
Orphanet250972
UMLSC2750798
MedGen442565
GARD0020687
Is cancer (heuristic)no

Also known as: CDCBM8 · polymicrogyria with optic nerve hypoplasia

Data availability: 8 ClinVar variants · 5 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordercentral nervous system disorderbrain disordercomplex cortical dysplasia with other brain malformationspolymicrogyria with optic nerve hypoplasia

Related subtypes (11): complex cortical dysplasia with other brain malformations 7, complex cortical dysplasia with other brain malformations 1, complex cortical dysplasia with other brain malformations 2, complex cortical dysplasia with other brain malformations 3, complex cortical dysplasia with other brain malformations 4, complex cortical dysplasia with other brain malformations 5, complex cortical dysplasia with other brain malformations 6, cortical dysplasia, complex, with other brain malformations 9, cortical dysplasia, complex, with other brain malformations 10, cortical dysplasia, complex, with other brain malformations 11, cortical dysplasia, complex, with other brain malformations 12

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

8 retrieved; paginated sample, class counts are floors:

6 uncertain significance, 2 conflicting classifications of pathogenicity

ClinVarVariant (HGVS)GeneClassificationReview
160175NM_018943.3(TUBA8):c.958C>T (p.Arg320Trp)TUBA8Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
425280NM_018943.3(TUBA8):c.967G>A (p.Val323Met)TUBA8Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1033914NM_018943.3(TUBA8):c.5G>A (p.Arg2Gln)TUBA8Uncertain significancecriteria provided, multiple submitters, no conflicts
1033915NM_018943.3(TUBA8):c.727C>T (p.Arg243Cys)TUBA8Uncertain significancecriteria provided, multiple submitters, no conflicts
448843NM_018943.3(TUBA8):c.1117C>T (p.Arg373Trp)TUBA8Uncertain significancecriteria provided, multiple submitters, no conflicts
4782NM_018943.3(TUBA8):c.4-21_4-8delTUBA8Uncertain significanceno assertion criteria provided
562019NM_018943.3(TUBA8):c.661C>T (p.Arg221Cys)TUBA8Uncertain significancecriteria provided, single submitter
592146NM_018943.3(TUBA8):c.728G>A (p.Arg243His)TUBA8Uncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
TUBA8SupportiveAutosomal recessivepolymicrogyria with optic nerve hypoplasia6

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TUBA8Orphanet:140957Autosomal dominant macrothrombocytopenia
TUBA8Orphanet:250972Polymicrogyria with optic nerve hypoplasia

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TUBA8HGNC:12410ENSG00000183785Q9NY65Tubulin alpha-8 chaingencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TUBA8Tubulin alpha-8 chainTubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TUBA8Other/UnknownnoTubulin, Alpha_tubulin, Tubulin_FtsZ_GTPase

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
apex of heart1
gastrocnemius1
hindlimb stylopod muscle1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TUBA8135broadmarkerhindlimb stylopod muscle, gastrocnemius, apex of heart

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TUBA84,465

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
TUBA8Q9NY6591.24

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 82. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane1543.8×0.017TUBA8
Transport of connexons to the plasma membrane1543.8×0.017TUBA8
Gap junction trafficking and regulation1475.8×0.017TUBA8
Gap junction trafficking1475.8×0.017TUBA8
Post-chaperonin tubulin folding pathway1475.8×0.017TUBA8
Formation of tubulin folding intermediates by CCT/TriC1423.0×0.017TUBA8
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding1407.9×0.017TUBA8
Activation of AMPK downstream of NMDARs1380.7×0.017TUBA8
RHO GTPases activate IQGAPs1346.1×0.017TUBA8
Sealing of the nuclear envelope (NE) by ESCRT-III1346.1×0.017TUBA8
HCMV Infection1326.3×0.017TUBA8
Chaperonin-mediated protein folding1300.5×0.017TUBA8
Gap junction assembly1292.8×0.017TUBA8
Nuclear Envelope (NE) Reassembly1292.8×0.017TUBA8
Selective autophagy1278.5×0.017TUBA8
Protein folding1259.6×0.017TUBA8
Assembly and cell surface presentation of NMDA receptors1253.8×0.017TUBA8
Cargo trafficking to the periciliary membrane1248.3×0.017TUBA8
Aggrephagy1248.3×0.017TUBA8
Carboxyterminal post-translational modifications of tubulin1237.9×0.017TUBA8
Recycling pathway of L11223.9×0.017TUBA8
COPI-independent Golgi-to-ER retrograde traffic1207.6×0.017TUBA8
Post NMDA receptor activation events1203.9×0.017TUBA8
Antimicrobial mechanism of IFN-stimulated genes1196.9×0.017TUBA8
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1193.6×0.017TUBA8
Activation of NMDA receptors and postsynaptic events1184.2×0.017TUBA8
Kinesins1178.4×0.017TUBA8
The role of GTSE1 in G2/M progression after G2 checkpoint1160.8×0.018TUBA8
Translocation of SLC2A4 (GLUT4) to the plasma membrane1154.3×0.018TUBA8
Autophagy1148.3×0.018TUBA8

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
spermatid development1145.3×0.008TUBA8
mitotic cell cycle1133.8×0.008TUBA8
microtubule cytoskeleton organization1121.2×0.008TUBA8

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TUBA800

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
TUBA873Binding:72, Functional:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1TUBA8

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TUBA873

Clinical trials & evidence

Clinical trials

Clinical trials: 0.